Table 2 Associations between plasma n-3 PUFAs and endometrial cancer recurrence^a

 wt%

0.62(0.54–0.67)

0.86(0.79–0.93)

1.23(1.07–1.33)

 Events/total(n/n)

3/65

5/66

5/64

 Model 1

1.00

1.87(0.43–8.1)

1.94(0.45–8.37)

 Model 2

1.00

1.74(0.41–7.4)

3.78(0.87–16.41)

 Model 3

1.00

2.15(0.48–9.66)

3.28(0.7–15.41)

 wt%

0.31(0.26–0.36)

0.53(0.46–0.6)

0.84(0.73–1.02)

 Events/total(n/n)

1/65

3/66

9/64

 Model 1

1.00

2.88(0.3–27.74)

9.71(1.23–76.73)

 Model 2

1.00

2.83(0.29–27.34)

7.3(0.89–59.68)

 Model 3

1.00

1.98(0.19–21.12)

6.02(0.7–52.06)

 wt%

0.39(0.35–0.42)

0.5(0.46–0.54)

0.63(0.6–0.7)

 Events/total(n/n)

1/65

6/66

6/64

 Model 1

1.00

6.57(0.78–55.51)

6.61(0.79–55.1)

 Model 2

1.00

8.48(0.99–72.72)

7.82(0.93–65.77)

 Model 3

1.00

7.02(0.73–67.61)

7.19(0.81–64.1)

 wt%

2.04(1.74–2.21)

2.62(2.47–2.82)

3.39(3.11–4)

 Events/total(n/n)

2/65

7/66

4/64

 Model 1

1.00

3.14(0.65–15.13)

1.97(0.36–10.86)

 Model 2

1.00

3.25(0.66–15.89)

1.59(0.29–8.82)

 Model 3

1.00

3.25(0.61–17.31)

1.22(0.2–7.54)

 wt%

2.88(2.61–3.06)

3.65(3.48–3.84)

4.8(4.31–5.67)

 Events/total(n/n)

2/65

4/66

7/64

 Model 1

1.00

1.77(0.32–9.67)

3.56(0.73–17.29)

 Model 2

1.00

1.69(0.3–9.42)

2.55(0.52–12.59)

 Model 3

1.00

1.57(0.27–9.14)

2(0.38–10.54)

 wt%

3.68(3.42–3.93)

4.53(4.35–4.72)

5.79(5.22–6.65)

 Events/total(n/n)

3/65

3/66

7/64

 Model 1

1.00

0.95(0.19–4.72)

2.4(0.62–9.37)

 Model 2

1.00

0.96(0.19–4.83)

2.3(0.59–9.02)

 Model 3

1.00

0.77(0.14–4.19)

1.7(0.4–7.33)